Monograph Details
|
|
Gastrointestinal Tract
> Nausea
|
|
KYTRIL |
| Manufacturer |
|
Roche Laboratories |
| Legal Classification |
|
Rx
|
| Pharmacological Class |
|
Selective 5-HT3 receptor antagonist. |
| Generic Name |
|
Granisetron (as HCl) 1mg/mL (contains benzyl alcohol); 0.1mg/mL (preservative-free); IV inj. |
| Also |
|
• KYTRIL TABLETS
|
| Indications |
|
Prevention of nausea and vomiting associated with chemotherapy (including high-dose cisplatin). Prevention and treatment of post-op nausea and vomiting. |
| Adults and Children |
|
Chemotherapy: give as an undiluted IV injection over 30 seconds or as a diluted IV infusion over 5 minutes. <2 years: not recommended; ≥2 years: 10micrograms/kg starting within 30 minutes of initiating chemotherapy, only on the days chemotherapy is given. Post-op (adults): infuse 1mg undiluted IV over 30 seconds. For prevention, give before induction of anesthesia or immediately before reversal of anesthesia. Post-op (children): not recommended. |
| Precautions |
|
Abdominal surgery. May mask progressive ileus and/or gastric distention. Pregnancy (Cat.B). Nursing mothers. |
| Interactions |
|
Caution with drugs that affect CYP450. |
| Adverse Reactions |
|
Headache, asthenia, diarrhea, constipation. |
| How Supplied |
Inj 1mg/mL single-use vial (1mL)—1
Inj 1mg/mL multidose vial (4mL)—1
Inj 0.1mg/mL single-use vial (1mL)—5
Tabs—2, 20 |
| Additional Resources |
|
• Related Prescribing Note |
|
|
|
|
